factually
Index/Topics/Alzheimer's Treatment with Lecanemab and Donanemab

Alzheimer's Treatment with Lecanemab and Donanemab

The use of lecanemab and donanemab for the treatment of early Alzheimer's symptoms, including their benefits and risks.

Fact-Checks

2 results
Jan 12, 2026
Most Viewed

What are the specific risks and monitoring requirements for patients receiving lecanemab or donanemab?

Two monoclonal antibodies—lecanemab (Leqembi) and donanemab (Kisunla)—offer modest slowing of early Alzheimer’s symptoms but carry specific, sometimes serious safety risks that require structured moni...

Jan 16, 2026

What are the common side effects and monitoring requirements for lecanemab and donanemab?

Lecanemab and donanemab are monoclonal anti‑amyloid antibodies approved for early Alzheimer’s disease that produce modest slowing of decline but carry important and common safety risks—most notably am...